{"id":"ld-i-trb","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL606611","moleculeType":"Small molecule","molecularWeight":"211.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This triple-drug combination targets multiple pathways in heart failure management: the diuretic reduces fluid overload and preload, the ACE inhibitor/ARB blocks the renin-angiotensin-aldosterone system to reduce afterload and prevent remodeling, and the beta-blocker decreases heart rate and contractility to reduce myocardial oxygen demand. Together, these agents work synergistically to improve cardiac hemodynamics and reduce mortality in heart failure patients.","oneSentence":"LD+I+TRB is a combination therapy that likely combines a diuretic (LD), an ACE inhibitor or ARB (I), and a beta-blocker (TRB) to reduce cardiac workload and improve heart function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:18:25.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure (likely systolic heart failure with reduced ejection fraction)"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT05591872","phase":"PHASE3","title":"Low Dose Heparin Factorial Trial","status":"UNKNOWN","sponsor":"Tabba Heart Institute","startDate":"2022-05-09","conditions":"Radial Artery Occlusion","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SD+I+TRB","LD+TRB"],"phase":"phase_3","status":"active","brandName":"LD+I+TRB","genericName":"LD+I+TRB","companyName":"Tabba Heart Institute","companyId":"tabba-heart-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LD+I+TRB is a combination therapy that likely combines a diuretic (LD), an ACE inhibitor or ARB (I), and a beta-blocker (TRB) to reduce cardiac workload and improve heart function. Used for Heart failure (likely systolic heart failure with reduced ejection fraction), Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}